Granular cell tumour in a patient with Crohn's disease treated with infliximab: coincidence or causal relationship?

Granular cell tumour (or Abrikossoff's tumour) was first described by Abrikossoff in 1926. This is a rare benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin. Usually, it presents as a solitary lesion, located mainly in the subcutaneous tissue of the head, or the neck, or in the oral cavity, such as a tongue lesion, although it may develop anywhere in the body. Approximately 1-2% of granular cell tumours are malignant. Granular cell tumours are extremely rare in patients with inflammatory bowel disease. To the best of our knowledge, granular cell tumours have never been reported in association either with Crohn's disease or scheduled infliximab treatment. Herein, we report a case of a granular cell tumour that presented as a subcutaneous skin nodule of the right lumbar area without any associated local or systemic symptoms in a 41-year-old woman with Crohn's disease who was receiving scheduled treatment with infliximab (5 mg/kg every 8 weeks) for 7 years.

Granular cell foci of the uterus in Donryu rats.

Eleven cases of uterine granular cell foci were observed in a total of 855 female Donryu rats. All the lesions were microscopical and focal or multifocal in nature, and composed of uniformly large cells with abundant granulated eosinophilic cytoplasm. Histopathologically, immunohistochemically and ultrastructurally they resembled granular cell tumours of the uterus reported in rats and mice. The development of granular cell foci may be the result of hormonal stimulation.

Granular cell tumor of the thyroid gland in a girl receiving high-dose estrogen therapy.

We describe the first case of a granular cell tumor of the thyroid. The tumor appeared while a girl was receiving high-dose estrogen therapy for tall stature. The tumor, however, did not contain estrogen or progesterone receptors. Although granular cell tumors occur twice as commonly in women as in men, the results of this case study do not provide evidence that tumor growth is mediated by direct estrogen or progesterone stimulation.

Effects of barbital on neuro-oncogenesis in a transplacental carcinogenicity model using F344 rats.

Effects of barbital (BB) on neuro-oncogenesis were examined in a rat transplacental carcinogenesis model. Pregnant F344 rats were divided into 7 groups. Dams in group I received subcutaneous injections of 10 mg/rat 1-butyl-1-nitrosourea (BNU) on the days 15, 18 and 21 of pregnancy and dams in groups II-IV, 1mg/rat BNU on the same time schedule. In addition to the treatment with BNU, dams in group IV were given 0.125% BB solution as their drinking water from the day 12 of pregnancy to parturition. Offspring in groups III and IV received 0.125% BB solution as drinking water from 4 weeks of age until the termination of the study. Animals in groups V and VI were given 0.25% and 0.125% BB solutions, respectively, in the peri- and postnatal period without BNU treatment. Dams in group VII received 250 mg/kg BB subcutaneously on the days 15, 18 and 21 of pregnancy. Offspring in all groups were observed until 105-116 weeks of age. High yields of neurogenic tumors, such as gliomas and neurinomas, were observed in group I. In groups II, III and IV, single cases of a chordoma, a granular cell tumor, and a neurinoma and a malignant reticulosis, which are known to occur spontaneously, were noted, although no gliomas were found. No neurogenic tumors were observed in groups V-VII. With regard to lesions other than those in neurogenic organs, a significant increase in liver tumors was observed in group III compared to group II. In contrast, lung tumors were not found in group III, while they were observed in groups II and IV. These results suggest that BB has no neuro-carcinogenic activity in the rat transplacental carcinogenesis model.